Trevi Therapeutics (TRVI) Short term Debt (2021 - 2023)

Trevi Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $7.5 million for Q1 2023.

• On a quarterly basis, Short term Debt rose 6.89% year-over-year to $7.5 million in Q1 2023; TTM through Mar 2023 was $7.5 million, a 6.89% increase from a year earlier, with the FY2022 full-year figure at $7.0 million, up 20.01% from the prior year.
• Short term Debt climbed to $7.5 million in Q1 2023 per TRVI's latest filing, from $7.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $7.5 million in Q1 2023 and bottomed at $583000.0 in Q1 2021.
• The 3-year median for Short term Debt is $7.0 million (2022), against an average of $5.4 million.
• Across the five-year window, Short term Debt jumped 1100.69% in 2022 and gained 6.89% in 2023, its largest moves.
• Year by year, Short term Debt stood at $5.8 million in 2021, then climbed by 20.01% to $7.0 million in 2022, then increased by 6.89% to $7.5 million in 2023.
• Per Business Quant, the three latest TRVI Short term Debt figures stand at $7.5 million (Q1 2023), $7.0 million (Q4 2022), and $7.0 million (Q3 2022).